from page 5 of the presentation: "it intends to utilise NS’...

from page 5 of the presentation:
"it intends to utilise NS’ robust wholesale and retail distribution platform to commercialise OBJ’s in-house developed products across Australia/New Zealand and beyond"
what "in-house" products? We don't have any, and we don't have any manufacturing expertise or facilities to produce our own products in-house. To start producing our own products would require 10s of millions of dollars which we don't have into a highly competitive market. And NS isn't generating that kind of cash flow. NS's cashflow will hardly cover our debt servicing commitments. The only product we have is IP built into someone else's products, and they're earning us a pittance. No distribution system, regardless of how flash or what expensive suburb it's located in produces any products, so the $12m property isn't going to do it for us.

" The combined business will harness OBJ’s patented technology to create and distribute products ". Again - what products are on the horizon apart from the Bodyguard? How will the combined business be able to contribute anything towards developing our own products in house that OBJ could not do on its own? And how will the Nutritional Systems part of the combined business be able to utilise our transdermal technology? It's all pretty fluff, pie in the sky and no substantial detail.

This company is becoming far removed from the original story I invested in - transdermal drug delivery. The only reason to approve this deal is because otherwise, OBJ is unlikely to survive. But I'm not interested in this proposed story, which is why I'll be out as soon as I can.